Problems For Vietnam's Pharma Industry

12 June 1997

Sales of Vietnam's 296 state- and privately-owned pharmaceuticalmanufacturing plants reached 4.50 billion dong (around $409 million) last year. However, the actual income generated by these plants was much lower than the value of their 19% market share, as a large proportion of their products was made using imported ingredients, according to the Vietnam Courier.

Vietnam's 37 companies licensed to conduct foreign trade in pharmaceuticals exported drugs worth $11.7 million in 1996, down 12% on the previous year, and their imports amounted to $350 million, up 25% on 1995.

Not Up To GMP Standards None of the country's pharmaceutical production plants meet international Good Manufacturing Practice standards. And, the VC comments, their distribution system is little better since very few Vietnamese producers know their market, failing to manufacture those products for which there is local demand.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight